Investidor Profissional Gestao de Recursos Ltda. Sells 1,199 Shares of Danaher Co. (NYSE:DHR)

Investidor Profissional Gestao de Recursos Ltda. cut its stake in shares of Danaher Co. (NYSE:DHR) by 29.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,814 shares of the conglomerate’s stock after selling 1,199 shares during the period. Danaher accounts for about 0.4% of Investidor Profissional Gestao de Recursos Ltda.’s portfolio, making the stock its 16th biggest position. Investidor Profissional Gestao de Recursos Ltda.’s holdings in Danaher were worth $782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. Swedbank AB acquired a new position in Danaher in the 1st quarter worth approximately $676,545,000. TD Asset Management Inc boosted its position in Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after acquiring an additional 675,952 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after purchasing an additional 563,546 shares in the last quarter. International Assets Investment Management LLC increased its stake in shares of Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after acquiring an additional 428,897 shares during the last quarter. Finally, Castle Hook Partners LP acquired a new stake in Danaher during the first quarter worth about $98,913,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DHR has been the subject of several analyst reports. TD Cowen increased their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. The Goldman Sachs Group raised their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Stifel Nicolaus upped their target price on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Barclays lowered their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Finally, Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Stock Down 3.7 %

DHR opened at $230.50 on Monday. Danaher Co. has a one year low of $206.30 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a market capitalization of $166.48 billion, a P/E ratio of 43.99, a price-to-earnings-growth ratio of 4.24 and a beta of 0.85. The business’s 50-day simple moving average is $262.20 and its 200-day simple moving average is $260.57.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.02 EPS. Analysts anticipate that Danaher Co. will post 7.51 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.